MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Sponsor: Pfizer

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05090566

Patient View

This study evaluates the Phase 2 dose and clinical benefit of elranatamab combined with other therapies in relapsed/refractory multiple myeloma patients. Eligible participants must have undergone at least three prior therapies and meet specific disease criteria. Exclusions include active infections and recent stem cell transplants. Interventions include combinations with nirogacestat and lenalidomide plus dexamethasone.

Patient Parameters

Program Overview

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Eligibility Criteria

Inclusion Criteria

  • Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy

  • Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody

  • Measurable disease defined by at least one of the following:

    1. Serum M-protein >/= 0.5 g/dL by SPEP
    2. Urinary M-protein excretion >/= 200 mg/24 hours by UPEP
    3. Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio

  • ECOG performance status 0 -1

  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade </= 1

Exclusion Criteria

  • Active plasma cell leukemia
  • Amyloidosis
  • Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
  • POEMS syndrome
  • Any active uncontrolled bacterial, fungal, or viral infection
  • Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
  • Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
  • Sub-Study A Only: Previous treatment with BCMA bispecific antibody
  • Sub-Study B Only: Previous treatment with BCMA directed therapy

Get This Program In Your Inbox

You can sign up and apply your patients for this program.